SCHEMBL2732013

SCHEMBL2732013

O=C(Cc1ccncc1)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FNTA P49354 16/20 1.00
FNTB P49356 16/20 1.00
SLC6A15 Q9H2J7 5/20 0.88
PTAFR P25105 2/20 0.76
HRH1 P35367 2/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29663139 1.00 FNTA (1.00) FNTAFNTBSLC6A15PTAFRHRH1
SCHEMBL6179026 0.91 FNTA (1.00) FNTAFNTBSLC6A15PTAFRHRH1
SCHEMBL14640320 0.90 FNTA (0.81) FNTAFNTBSLC6A15PTAFRHRH1
SCHEMBL7812134 0.90 FNTA (1.00) FNTAFNTB
SCHEMBL6178011 0.87 FNTA (0.77) FNTAFNTBSLC6A15HRH1
SCHEMBL6179778 0.87 FNTA (0.77) FNTAFNTBSLC6A15
SCHEMBL8880224 0.87 SLC6A15 (1.00) FNTAFNTBSLC6A15PTAFRHRH1
SCHEMBL6181380 0.87 FNTA (0.77) FNTAFNTBSLC6A15
SCHEMBL8879139 0.87 FNTA (1.00) FNTAFNTBSLC6A15PTAFRHRH1
SCHEMBL6178016 0.87 FNTA (0.77) FNTAFNTBSLC6A15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11324827-B2 Multifunctionalized polyethylene glycol derivative and preparation method therefor XIAMEN SINOPEG BIOTECH CO., LTD. (CN) 2022-05-10 US disclosed
US-20130225671-A1 Methods of Treating Seizure Disorders MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2013-08-29 US disclosed
US-20130225671-A1 Methods of Treating Seizure Disorders MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2013-08-29 US disclosed
US-20130225671-A1 Methods of Treating Seizure Disorders MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2013-08-29 US disclosed
WO-2012054724-A1 METHODS OF TREATING SEIZURE DISORDERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2012-04-26 WO disclosed
WO-2012054724-A1 METHODS OF TREATING SEIZURE DISORDERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2012-04-26 WO disclosed
EP-1123931-B1 Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases SCHERING CORP (US) 2005-06-01 EP disclosed
US-20030055065-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases BISHOP W ROBERT (US) 2003-03-20 US disclosed
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases BISHOP W ROBERT (US) 2002-06-06 US disclosed
US-6365588-B1 AS ANTINEOPLASTIC AGENT AND A POTENTIATING SCHERING CORPORATION 2002-04-02 US disclosed
EP-0723540-B1 TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORP (US) 2001-12-12 EP disclosed
EP-1123931-A1 Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases SCHERING CORPORATION (US) 2001-08-16 EP disclosed
US-6242458-B1 INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN SCHERING CORPORATION 2001-06-05 US disclosed
US-5665726-A ANTIALLERGIC, ANTIINFLAMMATORY AGENTS SCHERING CORPORATION (US) 1997-09-09 US disclosed
EP-0723540-A1 TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORPORATION (US) 1996-07-31 EP disclosed
WO-1995010516-A1 TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORPORATION (US) 1995-04-20 WO disclosed
US-5089496-A Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies SCHERING CORPORATION (US) 1992-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225671-A1 Methods of Treating Seizure Disorders NRAS, FAH, HMGCR FNTA 12/4885FNTB 37/4885SLC6A15 4587/4885
US-11324827-B2 Multifunctionalized polyethylene glycol derivative and preparation method therefor HDGF, F11, F12 FNTA 543/4885FNTB 403/4885SLC6A15 4113/4885
US-20030055065-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases RASGRP1, CCNA1, CCNA2 FNTA 516/4885FNTB 1222/4885SLC6A15 1804/4885
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases RASGRP1, CCNA1, CCNA2 FNTA 516/4885FNTB 1222/4885SLC6A15 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.